Biologics

Biologics CDMO is calling. Read more about the biopharma market outlook from Marty and Nigel.

Biologics CDMO Market – Mabion Approach to Establishing Cooperation

Many lifesaving biopharmaceuticals are suffering from a slump in venture funding. Novel recombinant protein based therapeutics, but also biosimilars are needed to fill the gaps in unmet patient needs. At Mabion we understand how to advance promising biosimilars and novel biotherapeutics to the clinic and from there to patients. Unfortunately, many promising biopharmaceutical innovations spanning novel recombinant protein therapeutics to biosimilars are being held back in the current, limiting funding climate, depriving patients from access to advanced therapies. Yet the urgency to close gaps in unmet patient care has never been greater. That is why we are launching the “Unlocking the Future of Therapeutics” competition a unique opportunity to support and accelerate biologics development and scale up for an oncology-targeted therapeutic. We are offering €500,000 credit in development services to support an exceptional therapeutic project. This can be a novel therapeutic, but might also be a biosimilar drug which expands patients access to lifesaving care. We have partnered with respected academic experts focused on cancer research to select the most promising candidate.

Mabion Launches €500,000 Services Contest to Support Next-Gen Oncology Breakthroughs

Modulation of the immune system to treat cancer and on novel approaches to further extend the efficacy of current and emerging immunotherapies led us to our current understanding of the melanoma immune microenvironment in humans and the mechanistic work supporting these observations.

Melanoma Immunotherapy Enhance by Immunity Activation

Cumulative incidence of P. falciparum blood-stage infection during a 6-month malaria season (irrespective of symptoms being present) after a single IV infusion of 10 mg kg−1 of CIS43LS (n = 110), 40 mg kg−1 of CIS43LS (n = 110) or placebo (n = 110). P. falciparum infections were detected by 18S qRT–PCR analysis of DBS collected during scheduled trial visits and unscheduled illness visits when malaria was suspected. DBS were collected before the administration of CIS43LS or placebo on day 0 and then on days 1, 3, 7, 14, 21 and 28 and every 2 weeks thereafter for a total of 24 weeks (day 168). Only DBS collected between days 21 and 168 were included. Estimates of the cumulative risk of infection are plotted along with the 95% CIs (shaded areas).

Single-Dose Monoclonal Antibody Therapy Offers Durable Protection Against Malaria

Worldwide preclinical and clinical R&D pipeline activity

Biopharma Drug Development Gaps Strategy

Mabion - 2025 CDMO Leadership Awards Champion in International Biologics

Winning Trust Through Mabion Biologics CDMO Excellence – exclusive interview with Marty Henehan

Mabion is a Champion of the 2025 International CDMO Leadership Award in Biologics

Mabion is a Champion of the 2025 International CDMO Leadership Award in Biologics

Mabion photo for Contract Pharma Magazine

Mabion’s Fill & Finish services in Contract Pharma Magazine

CDMO Leadership Awards 2025 - Mabion Finalist

Mabion is a Finalist in the CDMO Leadership Awards 2025 in the Biologics category

Previous 1 2 3 Next